Stocktoria
VACCINEX, INC. VCNX
OTC · stock · Pharmaceutical Preparations · website · IPO 2018-08-09
VACCINEX, INC. (VCNX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2024 revenue was $601,000 at a -3100.5% net margin.
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$3M
Net margin-3100.5%
Revenue trend · last 8y · up
How it ranks in Manufacturing · percentile among 1906 companies
Piotroski Fstronger than 27%
Net marginstronger than 6%
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VCNX | VACCINEX, INC. | 3/9 | — | — | — |
| ELAB | PMGC Holdings Inc. | 2/9 | — | — | — |
| VYNE | VYNE Therapeutics Inc. | 2/9 | — | — | — |
| BTAI | BioXcel Therapeutics, Inc. | 2/9 | — | — | — |
| SLN | Silence Therapeutics plc | 1/9 | -12.42 | — | -98.7% |
| QUCY | Quantum Cyber N.V. | 3/9 | — | — | — |
| MREO | Mereo BioPharma Group plc | 3/9 | — | — | — |
FAQ
Is VCNX financially healthy?
VACCINEX, INC.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does VCNX pay a dividend?
No, VACCINEX, INC. does not currently pay a dividend.
How profitable is VCNX?
In FY2024, VACCINEX, INC. had a net margin of -3100.5%.
Source: SEC EDGAR filings · CIK 0001205922 · US · as of 2024-12-31. facts plus Stocktoria's own computed scores — not investment advice.